No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Kanghui Pharmaceutical 2024 annual results forecast
Shaanxi Kanghui Pharmaceutical (603139.SH) issued a profit warning, expecting a net loss of about 85 million yuan for the year 2024.
Shaanxi Kanghui Pharmaceutical (603139.SH) released an announcement, stating that the company expects to achieve a net profit attributable to the parent company in 2024...
Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHSE:603139) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Kanghui Pharmaceuticals: Kanghui Pharmaceuticals Report for the Third Quarter of 2024
Kanghui Pharmaceutical\'s announcement on the main operating data for the first three quarters of 2024
Improved Revenues Required Before Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHSE:603139) Stock's 33% Jump Looks Justified
